U.S. Markets close in 4 hrs 39 mins

Balchem Corporation (BCPC)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
101.72-0.01 (-0.01%)
As of 11:19AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close101.73
Open102.74
Bid101.63 x 900
Ask101.81 x 800
Day's Range101.17 - 102.98
52 Week Range78.30 - 113.93
Volume21,995
Avg. Volume160,764
Market Cap3.287B
Beta (5Y Monthly)0.62
PE Ratio (TTM)40.37
EPS (TTM)2.52
Earnings DateNov 03, 2020 - Nov 09, 2020
Forward Dividend & Yield0.52 (0.52%)
Ex-Dividend DateDec 27, 2019
1y Target Est108.00
  • Balchem Corp (BCPC) Q2 2020 Earnings Call Transcript
    Motley Fool

    Balchem Corp (BCPC) Q2 2020 Earnings Call Transcript

    It is now my pleasure to introduce your host, Martin Bengtsson, Chief Financial Officer. Thank you for joining our conference call this morning to discuss the results of Balchem Corporation for the quarter ending June 30, 2020. My name is Martin Bengtsson, Chief Financial Officer.

  • GlobeNewswire

    Balchem Corporation Reports Record Second Quarter Sales of $173.4 Million, Net Earnings of $21.1 Million, GAAP EPS of $0.65, and Adjusted EPS of $0.85

    NEW HAMPTON, N.Y., July 31, 2020 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC) reported today record second quarter net earnings of $21.1 million for 2020, compared to net earnings of $19.8 million for the second quarter 2019.  Record second quarter adjusted net earnings(a) were $27.6 million, compared to $25.2 million in the prior year quarter, and adjusted EBITDA(a) was an all-time record of $43.9 million, compared to $40.0 million in the prior year quarter. Second Quarter 2020 Financial Highlights: * Net sales of $173.4 million, an increase of $11.8 million, or 7.3%, compared to the prior year quarter, with year over year sales growth in Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. * GAAP net earnings were $21.1 million, an increase of $1.3 million, or 6.5% from the prior year. These net earnings resulted in GAAP earnings per share of $0.65. * Adjusted net earnings of $27.6 million increased $2.3 million or 9.2% from the prior year, resulting in adjusted earnings per share(a) of $0.85. * Adjusted EBITDA was $43.9 million, an increase of $3.9 million, or 9.8%, from the prior year. * Quarterly cash flows from operations were $44.6 million for the second quarter 2020, an increase of 69.5% from the prior year, with quarterly free cash flow(a) of $37.0 million, an increase of 83.9% from the prior year.Recent Highlights: * Strong cash flows in the second quarter enabled the company to make $35.0 million of repayments of its revolving debt, lowering net debt to $142.2 million, with an overall leverage ratio on a net debt basis of 0.9. * The COVID-19 response effort has been a primary focus for the company since early in the first quarter. Our focus has been on employee safety first, keeping our manufacturing sites operational, satisfying customer needs, preserving cash and ensuring strong liquidity, and responding to changes in this dynamic market environment as appropriate. To date, all of our manufacturing sites are operating at near normal conditions enabling us to supply our customers with the important products and services they need, our research and development teams are advancing our innovation efforts, and all of our other employees are effectively carrying on their responsibilities and functions remotely. * We released our second annual Sustainability Report in April in support of our Environmental, Social, and Corporate Governance ideals.  We are committed to providing solutions for the health and nutrition needs of the world, acting as strong stewards of all our stakeholders, and making the world a healthier place.Ted Harris, Chairman, CEO, and President of Balchem said, “We are extremely pleased with these strong second quarter results which reflect record second quarter sales, net earnings, and earnings per share as well as sales growth in all three of our reporting segments."Mr. Harris added, "Our strong second quarter and year to date results reported today are a direct result of the extraordinary talents and efforts of the Balchem team as well as the strength of our market positions and the resilience of our business model." Results for Period Ended June 30, 2020 (unaudited) (Dollars in thousands, except per share data)   Three Months Ended June 30, Six Months Ended June 30,    2020 2019 2020 2019  Net sales $173,355  $161,554  $347,791  $318,583   Gross margin 55,380  53,918  110,711  103,013   Operating expenses 28,463  27,516  57,516  50,131   Earnings from operations 26,917  26,402  53,195  52,882   Other expense 944  1,521  2,732  3,208   Earnings before income tax expense 25,973  24,881  50,463  49,674   Income tax expense 4,848  5,052  9,570  11,062   Net earnings $21,125  $19,829  $40,893  $38,612              Diluted net earnings per common share $0.65  $0.61  $1.26  $1.19              Adjusted EBITDA(a) $43,885  $39,979  $86,256  $79,659   Adjusted net earnings(a) $27,562  $25,246  $54,003  $48,976   Adjusted net earnings per common share(a) $0.85  $0.77  $1.66  $1.51              Shares used in the calculations of diluted and adjusted net earnings per common share 32,470  32,583  32,492  32,540                 (a)See “Non-GAAP Financial Information” for a reconciliation of GAAP and non-GAAP financial measures. Financial Results for the Second Quarter of 2020: The Human Nutrition & Health segment generated quarterly sales of $97.4 million, an increase of $11.6 million or 13.5% compared to the prior year quarter. The increase was primarily driven by strong sales growth of chelated minerals and choline nutrients as well as increased sales into the food and beverage markets from both the legacy business and the Zumbro acquisition we closed in December 2019, partially offset by lower sales to food service related markets and the elimination of sales associated with the Reading, Pennsylvania manufacturing site that we divested in 2019. This segment generated quarterly earnings from operations of $15.5 million, an increase of $3.2 million or 25.6% compared to $12.3 million in the prior year quarter, primarily due to the aforementioned higher sales and lower selling expenses principally due to lower travel and a decrease in bad debt expense.  Excluding the effect of non-cash expense associated with amortization of acquired intangible assets of $4.8 million and $4.9 million for the second quarter of 2020 and 2019, respectively, adjusted earnings from operations(a) for this segment were $20.3 million, compared to $17.2 million in the prior year quarter.The Animal Nutrition & Health segment generated sales of $46.3 million, an increase of $2.9 million or 6.6% compared to the prior year quarter. The increase was primarily the result of higher volumes in both the ruminant species and monogastric species markets. Second quarter earnings from operations for this segment of $6.4 million increased $1.4 million or 27.4% compared to $5.0 million in the prior year quarter, primarily due to the aforementioned higher sales, certain lower raw material costs, and lower selling expenses principally due to lower travel. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets of $0.2 million in the second quarters of 2020 and 2019, adjusted earnings from operations for this segment were $6.6 million, compared to $5.2 million in the prior year quarter.The Specialty Products segment generated sales of $28.2 million, an increase of $3.3 million or 13.2% compared to the prior year quarter, primarily due to higher sales of ethylene oxide for the medical device sterilization market due to the incremental contribution of Chemogas, offset partially by lower legacy sales which were negatively impacted by reduced elective surgical procedures during the pandemic.  Second quarter earnings from operations for this segment were $8.0 million, versus $8.9 million in the prior year comparable quarter, a decrease of $0.9 million or 9.8%, primarily due to lower legacy ethylene oxide sales, product mix within plant nutrition, and higher operating expenses due to the acquisition of Chemogas. Excluding the effect of non-cash expense associated with amortization of acquired intangible assets for the second quarter of 2020 and 2019 of $1.6 million and $1.1 million, respectively, adjusted earnings from operations for this segment were $9.6 million, compared to $10.0 million in the prior year quarter.Consolidated gross margin for the quarter ended June 30, 2020 of $55.4 million increased by $1.5 million or 2.7%, compared to $53.9 million for the prior year comparable period. Gross margin as a percentage of sales was 31.9% as compared to 33.4% in the prior year period, a decrease of 143 basis points. The decrease was primarily due to mix and certain COVID-19 expenses, partially offset by certain lower raw material costs.  Operating expenses of $28.5 million for the quarter increased $0.9 million from the prior year comparable quarter, primarily due to incremental operating expenses related to the Chemogas and Zumbro acquisitions and a goodwill impairment charge related to business formerly included in the Industrial Products segment, partially offset by lower selling expenses driven by reduced travel and a decrease in bad debt expense. Excluding non-cash operating expenses associated with amortization of intangible assets of $6.2 million, operating expenses were $22.2 million, or 12.8% of sales.Interest expense was $1.0 million in the second quarter of 2020. Our effective tax rates for the three months ended June 30, 2020 and 2019 were 18.7% and 20.3%, respectively. The decrease in the effective tax rate from the prior year is primarily due to lower enacted tax rates from several states, certain higher tax credits, and excess tax benefits from stock-based compensation.For the quarter ended June 30, 2020, cash flows provided by operating activities were $44.6 million, and free cash flow was $37.0 million.  The $195.9 million of net working capital on June 30, 2020 included a cash balance of $76.4 million, which reflects repayments of the revolving debt of $35.0 million, and capital expenditures and intangible assets acquired of $7.9 million.Ted Harris said, “We are very proud of the strong performance reported in the second quarter of 2020.  The Balchem team has continued to respond extraordinarily well to the challenges and uncertainties created by the pandemic, with the safety of our employees as our top priority.  The progress we have made driving our business forward and advancing our key growth initiatives more than offset the headwinds we faced from the challenging macro-economic environment."Mr. Harris went on to add, “In addition, our strong cash conversion and the further improvement in our balance sheet over the course of the quarter provides financial strength as we continue to progress our organic growth initiatives and seek value-creating acquisitions.”Quarterly Conference CallA quarterly conference call will be held on Friday, July 31, 2020, at 11:00 AM Eastern Time (ET) to review second quarter 2020 results. Ted Harris, Chairman of the Board, CEO and President and Martin Bengtsson, CFO will host the call.  We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341), five minutes prior to the scheduled start time of the conference call.  The conference call will be available for replay two hours after the conclusion of the call through end of day Friday, August 14, 2020.  To access the replay of the conference call, dial 1-877-660-6853 (local dial-in 1-201-612-7415), and use conference ID 13707371.Segment InformationPreviously, Balchem's four reportable segments were: Human Nutrition & Health, Animal Nutrition & Health, Specialty Products, and Industrial Products.  However, effective the first quarter of 2020, in order to align with the Company's strategic focus on health and nutrition, allocation of resources, and evaluation of operating performance, Balchem revised its presentation to three reportable segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.  The Human Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries.  The Animal Nutrition & Health segment manufactures and supplies products to numerous animal health markets.  Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient agricultural market.  Sales and production of products outside of our reportable segments and other minor business activities are included in Other and Unallocated.  There was no change to the Consolidated Financial Statements. Forward-Looking StatementsThis release contains forward-looking statements, which reflect Balchem’s expectation or belief concerning future events that involve risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem’s expectations, including risks and factors identified in Balchem’s annual report on Form 10-K for the year ended December 31, 2019. Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook or other forward-looking statements as of any future date. Contact:  Mary Ann Brush, Balchem Corporation (Telephone: 845-326-5600) Selected Financial Data (unaudited) ($ in 000’s)Business Segment Net Sales: Three Months Ended June 30, Six Months Ended June 30,   2020 2019 2020 2019 Human Nutrition & Health $97,428  $85,872  $192,936  $171,021  Animal Nutrition & Health 46,344  43,480  94,985  86,841  Specialty Products 28,194  24,907  56,190  43,331  Other and Unallocated (1)  1,389  7,295  3,680  17,390  Total $173,355  $161,554  $347,791  $318,583  Business Segment Earnings Before Income Taxes: Three Months Ended June 30, Six Months Ended June 30,   2020 2019 2020 2019 Human Nutrition & Health $15,497   $12,338   $27,632   $26,041   Animal Nutrition & Health 6,430   5,045   14,474   10,301   Specialty Products 8,008   8,879   15,994   15,576   Other and Unallocated (1) (3,018) 140   (4,905) 964   Interest and other expense (944) (1,521) (2,732) (3,208) Total $25,973   $24,881   $50,463   $49,674             (1) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment.  Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $746 and $2,018 for the three and six months ended June 30, 2020, respectively, and $761 and $1,565 for the three and six months ended June 30, 2019 respectively (refer to note 4 for descriptions of these charges), and (ii) Unallocated amortization expense of $405 and $806 for the three and six months ended June 30, 2020, respectively, and $10 and $19 for the three and six months ended June 30, 2019, respectively, related to an intangible asset in connection with a company-wide ERP system implementation. Selected Balance Sheet Items      (Dollars in thousands) June 30, 2020 December 31, 2019   (unaudited)         Cash and Cash Equivalents $76,407  $65,672  Accounts Receivable, net 97,107  93,444  Inventories 81,546  83,893  Other Current Assets 8,802  11,937  Total Current Assets 263,862  254,946        Property, Plant & Equipment, net 217,003  216,859  Goodwill 522,929  523,998  Intangible Assets with Finite Lives, net 130,866  143,924  Right of Use Assets 6,159  7,338  Other Assets 10,437  8,617  Total Assets $1,151,256  $1,155,682        Current Liabilities $67,960  $92,258  Revolving Loan 218,569  248,569  Deferred Income Taxes 57,237  56,431  Derivative Liabilities 2,168  2,103  Long-Term Obligations 12,799  12,654  Total Liabilities 358,733  412,015        Stockholders' Equity 792,523  743,667        Total Liabilities and Stockholders' Equity $1,151,256  $1,155,682  Balchem Corporation Condensed Consolidated Statements of Cash Flows (Dollars in thousands) (unaudited)  Six Months Ended June 30,   2020 2019 Cash flows from operating activities:     Net earnings $40,893   $38,612   Adjustments to reconcile net earnings to net cash provided by operating activities:     Depreciation and amortization 25,294   21,732   Stock compensation expense 4,501   3,622   Other adjustments 2,697   (2,187)  Changes in assets and liabilities (6,205)  (12,967)    Net cash provided by operating activities 67,180   48,812         Cash flows from investing activities:     Cash paid for acquisitions, net of cash acquired —   (94,690)  Capital expenditures and intangible assets acquired (13,265)  (14,714)  Proceeds from insurance and sale of assets 22   2,729   Purchase of convertible note (350)  (1,000)    Net cash used in investing activities (13,593)  (107,675)        Cash flows from financing activities:     Proceeds from revolving loan 10,000   108,569   Principal payments on revolving loan (40,000)  (36,000)  Principal payments on acquired debt —   (12,222)  Proceeds from stock options exercised 6,802   1,809   Dividends paid (16,704)  (15,135)  Purchase of treasury stock (3,025)  (727)    Net cash (used in) provided by financing activities (42,927)  46,294         Effect of exchange rate changes on cash 75   (25)        Increase (decrease) in cash and cash equivalents 10,735   (12,594)        Cash and cash equivalents, beginning of period 65,672   54,268   Cash and cash equivalents, end of period $76,407   $41,674   Non-GAAP Financial InformationIn addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial performance and our future results. The non-GAAP financial measures disclosed by the company exclude certain business combination accounting adjustments and certain other items related to acquisitions, certain unallocated equity compensation, and certain one-time or unusual transactions. These non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations from these results should be carefully evaluated. Management believes that these non-GAAP measures provide useful information about the Company's core operating results and thus are appropriate to enhance the overall understanding of the Company's past financial performance and its prospects for the future. The non-GAAP financial measures in this press release include adjusted gross margin, adjusted earnings from operations, adjusted net earnings and the related adjusted per diluted share amounts, EBITDA, adjusted EBITDA, adjusted income tax expense, and free cash flow. EBITDA is defined as earnings before interest, other expense/income, taxes, depreciation and amortization. Adjusted EBITDA is defined as earnings before interest, other expense/income, taxes, depreciation, amortization, stock-based compensation, transaction and integration costs, indemnification settlements, legal settlements, ERP implementation costs, unallocated legal fees, the fair valuation of acquired inventory, goodwill impairment, and restructuring costs.  Adjusted income tax expense is defined as income tax expense adjusted for the impact of ASU 2016-09.  Free cash flow is defined as net cash provided by operating activities less capital expenditures and capitalized ERP implementation costs.Set forth below are reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.Table 1Reconciliation of Non-GAAP Measures to GAAP (Dollars in thousands, except per share data) (unaudited)  Three Months Ended June 30, Six Months Ended June 30,   2020 2019 2020 2019 Reconciliation of adjusted gross margin         GAAP gross margin $55,380  $53,918  $110,711  $103,013  Inventory valuation adjustment (2) —  —  208  —  Amortization of intangible assets (3) 742  661  1,466  1,395  Adjusted gross margin $56,122  $54,579  $112,385  $104,408            Reconciliation of adjusted earnings from operations         GAAP earnings from operations $26,917  $26,402  $53,195  $52,882  Inventory valuation adjustment (2) —  —  208  —  Amortization of intangible assets (3) 6,985  6,128  13,964  11,970  Transaction and integration costs, ERP implementation costs, and unallocated legal fees (4) 746  761  2,018  1,565  Goodwill impairment (5) 1,228  —  1,228  —  Adjusted earnings from operations $35,876  $33,291  $70,613  $66,417            Reconciliation of adjusted net earnings         GAAP net earnings $21,125  $19,829  $40,893  $38,612  Inventory valuation adjustment (2) —  —  208  —  Amortization of intangible assets (3) 7,056  6,199  14,105  12,112  Transaction and integration costs, ERP implementation costs, and unallocated legal fees (4) 746  761  2,018  1,565  Goodwill impairment (5) 1,228  —  1,228  —  Income tax adjustment (6) (2,593) (1,543) (4,449) (3,313) Adjusted net earnings $27,562  $25,246  $54,003  $48,976            Adjusted net earnings per common share - diluted $0.85  $0.77  $1.66  $1.51  The following table sets forth a reconciliation of Net Income calculated using amounts determined in accordance with GAAP to EBITDA and to Adjusted EBITDA for the three and six months ended June 30, 2020 and 2019.Table 2 (unaudited)  Three Months Ended June 30, Six Months Ended June 30,  2020 2019 2020 2019 Net income - as reported $21,125  $19,829  $40,893  $38,612  Add back:         Provision for income taxes 4,848  5,052  9,570  11,062  Other expense 944  1,521  2,732  3,208  Depreciation and amortization 12,674  10,825  25,153  21,590  EBITDA 39,591  37,227  78,348  74,472  Add back certain items:         Non-cash compensation expense related to equity awards 2,320  1,991  4,454  3,622  Inventory valuation adjustment (2) —  —  208  —  Transaction and integration costs, ERP implementation costs, and unallocated legal fees (4) 746  761  2,018  1,565  Goodwill impairment (5) 1,228  —  1,228  —  Adjusted EBITDA $43,885  $39,979  $86,256  $79,659  The following table sets forth a reconciliation of our GAAP effective income tax rate to our non-GAAP effective income tax rate for the three and six months ended June 30, 2020 and 2019.Table 3 (unaudited)  Three Months Ended June 30,  2020 Effective Tax Rate 2019 Effective Tax Rate GAAP Income Tax Expense $4,848  18.7% $5,052  20.3% Impact of ASU 2016-09 (7)  673    98    Adjusted Income Tax Expense $5,521  21.3% $5,150  20.7%   Six Months Ended June 30,  2020 Effective Tax Rate 2019 Effective Tax Rate GAAP Income Tax Expense $9,570  19.0% $11,062  22.3% Impact of ASU 2016-09 (7) 830    209    Adjusted Income Tax Expense $10,400  20.6% $11,271  22.7%           The following table sets forth a reconciliation of net cash provided by operating activities to free cash flow for the three and six months ended June 30, 2020 and 2019. Table 4 (unaudited)  Three Months Ended June 30, Six Months Ended June 30,   2020 2019 2020 2019 Net cash provided by operating activities $44,615  $26,329  $67,180  $48,812  Capital expenditures and capitalized ERP implementation costs (7,595) (6,200) (12,747) (14,688) Free cash flow $37,020  $20,129  $54,433  $34,124  (2) Inventory valuation adjustment: Business combination accounting principles require us to measure acquired inventory at fair value. The fair value of inventory reflects the acquired company’s cost of manufacturing plus a portion of the expected profit margin. The non-GAAP adjustment to our cost of sales excludes the expected profit margin component that is recorded under business combination accounting principles. We believe the adjustment is useful to investors as an additional means to reflect cost of sales and gross margin trends of our business.   (3) Amortization of intangible assets: Amortization of intangible assets consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets, capitalized loan issuance costs, and other intangibles acquired primarily in connection with business combinations. We record expense relating to the amortization of these intangibles in our GAAP financial statements. Amortization expenses for our intangible assets are inconsistent in amount and are significantly impacted by the timing and valuation of an acquisition. Consequently, our non-GAAP adjustments exclude these expenses to facilitate an evaluation of our current operating performance and comparisons to our past operating performance.   (4) Transaction and integration costs, ERP implementation costs and unallocated legal fees: Transaction and integration costs related to acquisitions and divestitures are expensed in our GAAP financial statements. ERP implementation costs related to a company-wide ERP system implementation are expensed in our GAAP financial statements. Unallocated legal fees for transaction-related non-compete agreement disputes are expensed in our GAAP financial statements. Management excludes these items for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures. We believe that excluding these items from our non-GAAP financial measures is useful to investors because these are items associated with each transaction and are inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.   (5) Goodwill impairment: A goodwill impairment charge related to business formerly included in the Industrial Products segment is expensed in our GAAP financial statements.  Management excludes this item for the purposes of calculating Adjusted EBITDA and other non-GAAP financial measures.  We believe that excluding this item from our non-GAAP financial measures is useful to investors because this item is inconsistent in amount and frequency causing comparison of current and historical financial results to be difficult.   (6) Income tax adjustment: For purposes of calculating adjusted net earnings and adjusted diluted earnings per share, we adjust the provision for (benefit from) income taxes to tax effect the taxable and deductible non-GAAP adjustments described above as they have a significant impact on our income tax (benefit) provision. Additionally, the income tax adjustment is adjusted for the impact of adopting ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting” and uses our non-GAAP effective rate applied to both our GAAP earnings before income tax expense and non-GAAP adjustments described above. See Table 3 for the calculation of our non-GAAP effective tax rate.   (7) Impact of ASU 2016-09: The primary impact of ASU No. 2016-09, "Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09"), was the recognition during the three and six months ended June 30, 2020 and 2019, of excess tax benefits as a reduction to the provision for income taxes and the classification of these excess tax benefits in operating activities in the consolidated statement of cash flows instead of financing activities.

  • Northern Trust Universe Data: Institutional Investment Returns Rebound Amid COVID-19 Market Recovery
    Business Wire

    Northern Trust Universe Data: Institutional Investment Returns Rebound Amid COVID-19 Market Recovery

    The Northern Trust Universe had a median plan return of 10.6% in the second quarter, as equity markets rebounded.